so I have been analyzing Biogen and have gone with a short position. They focus on MS drugs and there are newer options which patients and doctors have gravitated to based on subredits, FB pages and just web medical recommendations which are vague but do not list a ton of their drugs high on their lists.
One of their main drugs went generic recently. They have another one that got approved, but seems like people like other options.
Finally, I am wondering with the drop in the value of the Euro, would they, like any international company have a decrease in dollar profits? it is their second biggest market. what is everyone's thoughts?
Leave a Reply